Established in **1968**, Alkali Metals Limited (**AML**) is a veteran Indian specialty chemical manufacturer and a recognized **Export House** by the Directorate General of Foreign Trade (DGFT). Originally a pioneer in **Sodium Metal** production, the company has evolved into a sophisticated manufacturer of high-reactivity intermediates, reagents, and **Active Pharmaceutical Ingredients (APIs)**. AML serves as a critical link in the global supply chain for the pharmaceutical, agrochemical, and fine chemical industries. --- ### **Core Competencies & Integrated Product Portfolio** AML specializes in complex chemical synthesis, particularly involving alkali metals and pyridine chemistry. The company’s portfolio is built around high-tech building blocks used in organic synthesis. | Category | Key Products & Derivatives | | :--- | :--- | | **Sodium Derivatives** | **Sodium Amide**, **Sodium Alkoxides**, **Sodium Hydride**, **Sodium Azide** | | **Pyridine Chemistry** | **Amino Pyridines**, **Pyridine Derivatives**, **Cyclic Compounds** | | **Specialty Chemicals** | **Tetrazoles**, **Fine Chemicals**, **Intermediates for APIs** | | **Life Sciences** | **Active Pharmaceutical Ingredients (APIs)** | **Operational Scale:** * **Volume:** In the most recent fiscal cycle, the company sold **1,068 MT** of finished products. * **Quality Standards:** All operations are conducted under **ISO 9001 (Quality)** and **ISO 14001 (Environmental)** certifications, utilizing **Integrated Management Systems** to meet stringent international regulatory requirements. --- ### **Strategic Manufacturing Infrastructure & R&D** AML operates three specialized manufacturing units strategically located in South India to optimize logistics and pharmaceutical industry integration: * **Unit-I (Uppal, Hyderabad):** Serves as the registered office and primary manufacturing site. * **Unit-II (Dommara Pochampally, Hyderabad):** A versatile multi-product facility designed for diverse chemical reactions. * **Unit-III (JN Pharma City, Visakhapatnam):** Located within a dedicated pharmaceutical industrial park, providing proximity to major API customers. **Innovation and Process Optimization:** The company is recognized by the **Department of Science and Technology** as an approved **'In-house R&D Facility'**. * **Investment:** R&D expenditure increased to **₹1.34 Crore** in **FY 2023-24** (up from **₹1.11 Crore**). * **Focus Areas:** Development of new molecules, automation of repetitive tasks, and indigenous technology absorption. * **Sustainability:** AML employs **Hydrogen recovery** and **Nitrous oxide generation** plants across all units to recycle fuels and reduce operational costs. --- ### **Global Expansion & "Vision 2030" Strategy** AML is aggressively transitioning from a domestic player to a global specialty chemical powerhouse. The strategy focuses on geographic diversification to mitigate regional volatility. * **Global Footprint:** Currently operating across **four continents**, AML aims to expand its presence to more than **30 countries** by **2027**, with a focus on **Eastern Europe**. * **China Market Entry:** AML has identified China as a high-growth territory with specific revenue milestones: * **2027 Target:** **$1 Million (₹8.6 Crores)** * **2030 Target:** **$5 Million (₹43.42 Crores)** * **Market Resilience:** The company is aligning its internal growth targets with the projected **9% p.a. growth** of the broader chemical industry while utilizing agile decision-making to navigate geopolitical conflicts. --- ### **Financial Performance & Capital Structure** The company has faced a challenging macro environment characterized by lower realizations and compressed margins. While turnover has remained relatively stable, profitability has been impacted by global industry slowdowns. **Comparative Financial Summary:** | Metric (₹ in Crore) | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Turnover** | **82.33** | **82.86** | **88.23** | | **Net Profit / (Loss)** | **(5.80)** | **0.51** | **2.82** | | **Foreign Exchange Earnings** | **-** | **45.40** | **57.12** | | **Dividend Recommended** | **₹0.50 / share** | **₹1.00 / share** | **₹2.00 / share** | **Banking and Credit Profile:** * **Credit Ratings (June 2025):** Long-term: **[ICRA] BB+ (Negative)**; Short-term: **[ICRA] A4+**. * **Working Capital:** Maintains a **Cash Credit limit of ₹18 Crore**, including an **Export Packing Credit (EPC) sub-limit of ₹12.5 Crore**. * **Debt Cost:** Recent EPC borrowings are priced at **T-Bill plus 1.15% (approx. 7.88% p.a.)**. * **Liabilities:** The company carries an interest-free sales tax deferment liability (Target 2000 Scheme), amortized under **Ind AS 109**. --- ### **Risk Management & Mitigation Framework** AML navigates a complex landscape of market, financial, and operational risks. **1. Market & Geopolitical Risks:** * **Over-capacity:** Post-pandemic inventory de-stocking has led to a domestic and global supply glut. AML is responding by rationalizing **capacity utilization** and optimizing **fixed costs**. * **European Volatility:** Geopolitical tension in Europe has softened demand in key export markets. **2. Financial Risk Management:** * **Foreign Exchange:** As a major exporter (**65% of turnover** in FY23), AML is exposed to currency swings. It generally leaves exposures **un-hedged** when the INR appreciates. * **Credit Risk:** Mitigated by dealing exclusively with **high credit rating counterparties** and mandatory credit verification. * **Liquidity:** Managed by availing credit facilities on a strictly need-to-borrow basis. **3. Operational & Regulatory Risks:** * **Cybersecurity:** Following a **₹19 Lakh** loss to business email compromise in **2022**, the company has heightened digital security protocols. * **Compliance:** AML is settling outstanding export-related customs duties (remaining balance of **₹10.63 Lakhs** of an original **₹44.93 Lakhs**). * **Capital Expenditure:** Due to current economic headwinds, major **Capex** has been deferred to preserve liquidity. **4. Employee Obligations:** The company maintains a defined benefit gratuity fund. As of **March 31, 2025**, the **Present Value of Obligation** stood at **339.22 Lakhs**, with a **Net Liability of ₹133.70 Lakhs** after accounting for plan assets.